Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pushing Hard On PD-1, Merck Signs Trio Of Combo Development Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s oncology build-up is continuing, even as it tightens focus and squeezes spending in other parts of its business as part of an ongoing “reshaping” that CFO Peter Kellogg said will help to maximize “core in-line assets and key pipeline programs” that are critical for growth.

You may also be interested in...



Dr. Reddy’s Chairman GV Prasad On Innovation, Biosimilars And Global Challenges: An Interview With PharmAsia News

GV Prasad, Chairman of the $2.13 billion Indian drug firm Dr. Reddy's Laboratories Ltd. is preparing to take his company from predominantly generics to super generics and untapped innovative niche products. His pet project is lower risk innovation via reverse translation by solving problems with existing molecules.

Emerging Markets Earnings Roundup: Merck, AstraZeneca (Part 6)

Merck comes up short on goal to reach 25% of total sales from emerging markets and sees headwinds on diabetes. AstraZeneca is full-steam ahead on China with headcount expansion in 2013 paving the way for gains in 2014, CEO Pascal Soriot says.

Two Approaches To PD-1 Blocker Pediatric Studies Could Help Clarify Biomarker’s Role

Merck plans to enrich its Phase II study for MK-3475 with patients whose tumors express PD-L1; Bristol would take all comers in its Phase I/II trial of nivolumab.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel